Kadmon Holdings Inc (NYSE:KDMN) shares rose 6.2% on Tuesday . The stock traded as high as $2.27 and last traded at $2.24. Approximately 692,599 shares traded hands during mid-day trading, a decline of 20% from the average daily volume of 868,677 shares. The stock had previously closed at $2.11.
KDMN has been the subject of several recent analyst reports. Zacks Investment Research upgraded Kadmon from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research note on Friday, February 22nd. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Kadmon in a research report on Tuesday, March 12th. Finally, Citigroup upgraded Kadmon from a “neutral” rating to a “buy” rating and set a $2.77 price objective for the company in a research report on Tuesday, February 26th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Kadmon has a consensus rating of “Hold” and a consensus target price of $8.36.
The company has a quick ratio of 3.85, a current ratio of 3.89 and a debt-to-equity ratio of 0.60.
Kadmon (NYSE:KDMN) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.18). Kadmon had a negative net margin of 2,487.49% and a negative return on equity of 91.12%. On average, research analysts forecast that Kadmon Holdings Inc will post -0.67 EPS for the current year.
Large investors have recently added to or reduced their stakes in the business. Amalgamated Bank bought a new stake in Kadmon during the fourth quarter valued at about $25,000. Capital Investment Advisors LLC bought a new stake in Kadmon during the fourth quarter valued at about $26,000. IFP Advisors Inc grew its holdings in Kadmon by 54.5% during the fourth quarter. IFP Advisors Inc now owns 25,500 shares of the company’s stock valued at $49,000 after purchasing an additional 9,000 shares during the period. Metropolitan Life Insurance Co. NY grew its holdings in Kadmon by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 26,251 shares of the company’s stock valued at $55,000 after purchasing an additional 20,502 shares during the period. Finally, BNP Paribas Arbitrage SA bought a new stake in Kadmon during the first quarter valued at about $55,000. 65.40% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Kadmon (KDMN) Stock Price Up 6.2%” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.thelincolnianonline.com/2019/05/16/kadmon-kdmn-stock-price-up-6-2.html.
About Kadmon (NYSE:KDMN)
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.